Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer

Sponsor
Wuling Ou
Study ID
NCT02974933
Phase
PHASE2
Status
Unknown

Conditions

  • Nonsmall Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib combined with pemetrexed — DRUG
    For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression

Study Details

The purpose of this study is to evaluate the efficacy of apatinib mesylate combined with pemetrexed alone in advanced non-small cell lung cancer patients in the second or second line of treatment of progression-free survival

Key Dates

Start date
Nov 30, 2016
Status verified
Feb 2017
Primary completion
Nov 30, 2017
Completion
Nov 30, 2018

Study Design

Enrollment
48 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib
    combined with pemetrexed

Primary Outcome Measure

progression free survival [ Time Frame: 4 weeks ]

Central Contacts

Related Studies